Cargando…

Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets

The anti-α4β7 integrin antibody vedolizumab (VDZ) is successfully used for the treatment of inflammatory bowel diseases. However, only a subgroup of patients respond to therapy. VDZ is administered at a fixed dose, leading to a wide range of serum concentrations in patients. Previous work from our g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Becker, Emily, Schweda, Anna, Ullrich, Karen A. -M., Voskens, Caroline, Atreya, Raja, Müller, Tanja M., Atreya, Imke, Neurath, Markus F., Zundler, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236604/ https://www.ncbi.nlm.nih.gov/pubmed/35575178 http://dx.doi.org/10.14309/ctg.0000000000000494

Ejemplares similares

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
por: Mühl, Laura, et al.
Publicado: (2021)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
por: Fuchs, Friederike, et al.
Publicado: (2017)

Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis
por: Besendorf, Laura, et al.
Publicado: (2022)

α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis
por: Melde, Michaela, et al.
Publicado: (2021)

Baseline levels of dynamic CD4(+) T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study
por: Allner, Clarissa, et al.
Publicado: (2020)

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo
por: Fischer, Anika, et al.
Publicado: (2016)

Increased Motility and Suppression of Ex Vivo–Expanded Regulatory T Cells Designed for Adoptive Transfer Therapy in Ulcerative Colitis
por: Müller, Tanja M., et al.
Publicado: (2023)

Targeting Immune Cell Trafficking – Insights From Research Models and Implications for Future IBD Therapy
por: Wiendl, Maximilian, et al.
Publicado: (2021)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
por: Rath, Timo, et al.
Publicado: (2018)

Anti‐β7 integrin treatment impedes the recruitment on non‐classical monocytes to the gut and delays macrophage‐mediated intestinal wound healing
por: Sommer, Katrin, et al.
Publicado: (2023)

Nr4a1-dependent non-classical monocytes are important for macrophage-mediated wound healing in the large intestine
por: Heidbreder, Karin, et al.
Publicado: (2023)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating Lymphocytes
por: Atreya, Imke, et al.
Publicado: (2022)

Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders
por: Wiesinger, Manuel, et al.
Publicado: (2017)

Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
por: Lichnog, Charlotte, et al.
Publicado: (2019)

Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial
por: Voskens, Caroline J, et al.
Publicado: (2021)

Intestinal Mucosal Wound Healing and Barrier Integrity in IBD–Crosstalk and Trafficking of Cellular Players
por: Sommer, Katrin, et al.
Publicado: (2021)

Circulating Adaptive Immune Cells Expressing the Gut Homing Marker α4β7 Integrin Are Decreased in COVID-19
por: Müller, Tanja M., et al.
Publicado: (2021)

Deciphering Novel Mechanistic and Pharmacokinetic Effects of Tofacitinib in Intestinal Inflammation: Expect the Unexpected
por: Atreya, Raja, et al.
Publicado: (2021)

IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality
por: Atreya, Raja, et al.
Publicado: (2022)

Editorial: Loss of Epithelial Barrier Integrity in Inflammatory Diseases: Cellular Mediators and Therapeutic Targets
por: Weidinger, Carl, et al.
Publicado: (2021)

Protective effect of the novel calcineurin inhibitor voclosporin in experimental colitis
por: Lindemann, Aylin, et al.
Publicado: (2023)

Manual cell selection in single cell transcriptomics using scSELpy supports the analysis of immune cell subsets
por: Dedden, Mark, et al.
Publicado: (2023)

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Endoscopic Therapy in Inflammatory Bowel Diseases
por: Neumann, Helmut, et al.
Publicado: (2015)

Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes?
por: Abdullah, Abdullah, et al.
Publicado: (2020)

Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
por: Atreya, Raja, et al.
Publicado: (2020)

Role of the IL23/IL17 Pathway in Crohn’s Disease
por: Schmitt, Heike, et al.
Publicado: (2021)

Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease
por: Klenske, Entcho, et al.
Publicado: (2019)

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma
por: Zundler, Sebastian, et al.
Publicado: (2023)

Regulation of Human Innate Lymphoid Cells in the Context of Mucosal Inflammation
por: Schulz-Kuhnt, Anja, et al.
Publicado: (2020)

Innate Lymphoid Cells as Regulators of Epithelial Integrity: Therapeutic Implications for Inflammatory Bowel Diseases
por: Schulz-Kuhnt, Anja, et al.
Publicado: (2021)

Functional Contribution and Targeted Migration of Group-2 Innate Lymphoid Cells in Inflammatory Lung Diseases: Being at the Right Place at the Right Time
por: Wirtz, Stefan, et al.
Publicado: (2021)

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
por: Billmeier, Ulrike, et al.
Publicado: (2016)

ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure
por: Schulz-Kuhnt, Anja, et al.
Publicado: (2020)

Interplay of GTPases and Cytoskeleton in Cellular Barrier Defects during Gut Inflammation
por: López-Posadas, Rocío, et al.
Publicado: (2017)

Healing of the epithelial barrier in the ileum is superior to endoscopic and histologic remission for predicting major adverse outcomes in ulcerative colitis
por: Rath, Timo, et al.
Publicado: (2023)

IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells
por: Ullrich, Karen Anne-Marie, et al.
Publicado: (2023)

The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis
por: Schmitt, Heike, et al.
Publicado: (2020)

Oligonucleotides—A Novel Promising Therapeutic Option for IBD
por: Scarozza, Patrizio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kipcnicbp0trjr7kjloi11i5f7